Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health
|
|
- Alice Wilkins
- 5 years ago
- Views:
Transcription
1 Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health
2 Thirty years of AIDS July 3, 1981
3 A generation in the shadow of AIDS...
4 Global Estimates of People Living with HIV/AIDS,
5 Thirty years into the epidemic Number of people living with HIV 4.0 Number of people newly infected with HIV 40 People newly infected with HIV and deaths due to AIDS (Millions) Number of deaths due to AIDS People living with HIV/AIDS (Millions) UNAIDS/WHO Epi update, 2009
6 Global estimates for adults and children 2009 People living with HIV New HIV infections in 2009 Deaths due to AIDS in million [ million] 2.6 million [ million] 1.8 million [ million] Each day people die of AIDS Each day more people on Antiretroviral Therapy
7 Over 7000 new HIV infections a day in 2009 About 97% are in low and middle income countries About 1000 are in children under 15 years of age About 6000 are in adults aged 15 years and older, of whom: almost 51% are among women about 41% are among young people (15-24)
8
9 Thirty years of AIDS First South African publication: 1983: two cases in homosexual men, both died in 1982
10 Thirty years of AIDS September 1986: The present status of AIDS cases in the RSA is: (i) South African residents 30 cases comprised of homosexual/bisexual men (26), heterosexual (I), blood transfusion AIDS (I) and haemophiliacs (2); all these are white males; R Sher, SAMJ, 1986
11 Thirty years of AIDS.. has a new microbe arisen like a phoenix from the cauldron of evolution and flourished here and now because of the special social and sexual circumstances of the times? Ruben Sher, SAMJ 1986
12 A decade of denial
13 HIV trends in sub-saharan Africa
14 Young women at highest risk in Africa
15 HIV prevalence, by sex and age, South Africa, 2008 Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N, Van Zyl J, Parker W, Zungu NP, Pezi S & the SABSSM III Implementation Team (2009) South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers? Cape Town: HSRC Press
16 Reality Check: a question of scale Norway : total population 4.9 millio n South Africa: people living with HIV 5.3 millio n
17 Back on track... South Africa has rapidly scaled up its prevention of mother to child HIV transmission (PMTCT) programmes. By 2010, PMTCT was offered at 98% of health facilities with virtual universal coverage of mothers booking and delivering in health facilities. In 2010, early transmission from mother to child was found to be 3.5 percent in South Africa, and only 1.1 percent of 4- to 8-week-old infants in the country were infected with HIV. Rollout of antiretroviral therapy continues to be successful, with 1.4 million persons started on antiretroviral therapy as at the end of June Treatment initiation rates have reached 30,000 per month. Revision of the treatment guidelines in 2009 and 2011 has increased the threshold for ART treatment to CD4 count 350, and to initiate all HIV positive infants regardless of CD4 level
18 Game Changer interventions proposed in the Draft NSP : Scaling up and improving the quality of key prevention and treatment programmes, including male and female condom distribution (including for key populations), MMC, prevention of mother to child transmission, and ART; Combination prevention interventions that are targeted depending on epidemiology; Introducing new prevention interventions rapidly as informed by evidence, e.g. microbicides, and pre-exposure prophylaxis for key populations; and Protecting children and reducing their HIV and TB vulnerability, including keeping girls in school for as long as possible.
19 Antiretroviral treatment: saving lives
20 Annual AIDS-related deaths by region:
21 Antiretroviral treatment is saving lives At the end of 2009, people were receiving antiretroviral therapy in lowand middle income countries This is an increase of over 1.2 million people from December This represents a 30% rise from a year earlier and a 13- fold increase in six years.
22 Number of people receiving antiretroviral therapy in low- and middleincome countries, by region,
23 A long way to go to achieve universal access to treatment Among 144 low- and middle-income countries, eight had already achieved universal access to antiretroviral therapy at the end of 2009, providing treatment to at least 80% of patients in need. WHO
24 Is universal access possible? Successful provision of universal treatment access may be critically dependent on reducing the number of new infections 6.6 million are now on antiretroviral treatment (ART) 9 million are waiting to receive it For every person starting ART two people are newly infected 20 million more people predicted to acquire HIV by 2031: Increasing potential treatment costs up to $35 billion a year. Shattock IAS 2011
25 A renaissance of hope This is an exciting time for science. These studies offer unprecedented opportunities to expand the toolkit for prevention. Gottfried Hirnschall, Director, HIV/AIDS, World Health Organization As we get more scientific data, the ability to contain the epidemic by multiple weapons gets better and better. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases This can be a momentum changer. This could be an epidemic where we see a major turnaround in a single generation. Paul DeLay, Deputy Executive Director, UNAIDS
26 The State of HIV Prevention Strategies: 2010
27 The State of HIV Prevention Strategies: 2011? Condoms Male Circumcision ARV Prophylaxis: PMTCT Sterile needle exchange for intravenous drug users ARV Prophylaxis: PEP, PrEP Antiretroviral based Microbicides Vaccines Counselling & Testing HSV-2 Suppressive therapy Cervical Barriers STI Treatment HIV PREVENTION STRATEGIES
28 Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/coital) Exposure (pre-coital/coital) After infection Male circumcision Oral pre exposure prophylaxis (daily PrEP) Topical PrEP (daily gels or intra-vaginal rings (microbicides) Preventive Vaccines Oral pre exposure prophylaxis (intermittent PrEP) Coitally dependent topical PrEP (microbicides) Oral post exposure prophylaxis (PEP) Anti-retroviral therapy Immediate treatment of positive partners in discordant couples Treatment for prevention in all who test positive for HIV (T4P) Behavioural & structural components AVAC, Shattock IAS 2011
29 New biomedical intervention strategies Study Prime boost HIV Vaccine (Thai RV144) 1% tenofovir gel (Caprisa 004, Karim et al.) TDF/FTC oral PrEP in MSM (iprex, Grant et al 2010) Medical male circumcision (MMC) (Orange Farm, Rakai, Kisumu) TDF/FTC oral PrEP in heterosexuals (TDF2, CDC) TDF oral PrEP in serodiscordant Partner (Partners PrEP) TDF/FTC oral PrEP in serodiscordant Partner (Partners PrEP) Immediate ART for positive Partners (HPTN052) 0% % Effect size (CI) 31% (1, 51) 39% (6, 60) 44% (15, 63) 57% (42, 68) 63% (22, 83)* 62% (34, 78)* 73% (49, 85)* 96% (82, 99)* *Provisional Efficacy
30 Multi component prevention The failure of silver bullet single biomedical interventions has opened the way for a wider acceptance of the need for a multi component prevention approach HIV prevention requires a comprehensive approach, applying a combination of strategies that respond to the real needs of real people Only does not work for HIV prevention Coates et al, Lancet 2008
31 From ABC to A-Z Need to acknowledge the false divide between biomedical and behavioural strategies Implementation of successful biomedical interventions also provide opportunities to refocus on behaviour modifications, including: Strategies to reduce HIV risk linked to alcohol use Delaying sexual debut Decreasing HIV risk from drug abuse, including needle exchange programmes Reducing the risk from multiple concurrent partnerships
32 Medical Male Circumcision
33 Male Circumcision: bridging from research to reality Medical male circumcision reduced the risk of HIV infection in men in three randomised controlled trials by close to 60% Estimated that one HIV infection could be prevented for every five to 15 men circumcised in settings with high levels of HIV and low rates of male circumcision, at a cost of US $150 to $900 per HIV infection averted over 10 years Since 2007, WHO and UNAIDS have recommended male circumcision as an important HIV prevention strategy in countries with high rates of heterosexual HIV transmission and low rates of male circumcision.
34 Annual male circumcisions for HIV prevention in eight countries* in Eastern and Southern Africa, Thousands * Kenya, Malawi, Namibia, Rwanda, South Africa, Swaziland, Zambia and Zimbabwe Hankins IAS 2011
35 Achievement toward target of 80% coverage Hankins, 2011: Courtesy Emmanuel Njeuhmeli, PEPFAR
36 Male Circumcision: bridging from research to reality In 2010, South Africa instituted an aggressive rollout of a national medical male circumcision (MMC) programme. The goal is to reach 80% of men aged (approximately 4.3 million men) by As of June 2011, medical male circumcisions had been conducted.
37 Lessons from medical male circumcision for other new prevention technologies Need to address concerns about: Partial protection, risk compensation, behavioural inhibition Promotion of combination protection Gender equity Stigma and discrimination Mobilising demand and ensuring supply Competition for financial, human and service resources Hankins 2009
38 A vaccine for AIDS?
39 RV144 Acquisition Endpoint: Modified Intent to Treat (mitt) Probability of HIV-1 Infection (%) YEARS Placebo Vaccine Placebo Vaccine Vaccine infections: 51 Placebo infections: 74 p = 0.04 Efficacy: 31.2% 95% CI (OBF): 1.1, 51.2 month Events Efficacy 54% 60% 44% 36% 36%
40 Preventing mother- to-child transmission of HIV
41 PMTCT impact: infections averted among infants Infant infections averted Estimate of the annual number of infant infections averted through the provision of antiretroviral prophylaxis to HIV-positive pregnant women, globally, , UNAIDS 2009
42 Working towards an AIDS free generation by 2015
43 Elimination of MTCT by 2015? From talking to action... We can prevent mothers dying and babies becoming infected with HIV. That is why I am calling for the virtual elimination of mother-to-child transmission of HIV by 2015 Michel Sidibe, UNAIDS December 2009
44 Preventing mother-to-child transmission of HIV: Lessons of success and failure PMTCT led the way with combination prevention approaches: in promoting a four-pronged combination prevention approach in using treatment for prevention.
45 Antiretroviral prophylaxis: Pre-exposure Prophylaxis (PrEP) Antiretroviral microbicides
46 Pre-Exposure Prophylaxis Study Effect CAPRISA (TDF Gel) 39 50% iprex (Daily TDF) 44% FEM PrEP (Daily TDF) Stopped Partners (TFV/TDF) >70% Botswana (TDF) >60% Others in Progress Cohen IAS 2011
47 CAPRISA 004: HIV infection rates in the tenofovir and placebo gel groups: Kaplan-Meier survival probability 0.20 Probability of HIV infection Months of follow-up Cumulative HIV endpoints Years Cumulative women-years HIV incidence rates (Tenofovir vs Placebo) Effectiveness (p-value) 6.0 vs vs vs vs vs % (0.069) 50% (0.007) 47% (0.004) 40% (0.013) Placebo Tenofovir 39% (0.019) (0.017) p=0.019 p=0.017
48 PrEP for HIV prevention in men who have sex with men
49 Antiretroviral treatment: Treatment IS Prevention
50 HIV Treatment as Prevention? Compelling biological plausibility: ART reduces HIV in genital secretions Five observational reports What is the magnitude and durability of ART for prevention? Does early ART (for prevention) benefit an HIV infected person? POSITIVE RESULTS: Bunnell (JAIDS, 2007) Sullivan (IAS 2008) Donnell (Lancet, 2010) Romero (BMJ, 2010) NEGATIVE RESULTS: Wang (IAS, JAIDS, 2010) Cohen IAS 2011
51 HPTN discordant heterosexual couples 9 countries, 13 sites Randomization Immediate ART cells/uL AZT+3TC+EFV Deferred ART CD4 <250 Endpoints: i) HIV Transmission to partners ii) OIs and clinical Events iii) ART toxicity Cohen IAS 2011
52 HPTN 052 Modified by DSMB April 28, 2011 (DSMB meeting #11) Recommendation: Make the results available to the public (and study subjects) as soon as possible HPTN 052 is ongoing with all HIV infected subjects offered ART, regardless of CD4 count
53 HPTN 052 Prevention Results p<0.001 Cohen IAS 2011
54 HPTN 052: results Early ART prevented linked transmission of HIV Unlinked transmissions were noted despite intensive couples counseling Early ART reduced the number of clinical events observed
55 HPTN 052: Implications The HIV prevention effect demonstrated in HPTN 052 is the proof of a concept These results could inform The Test and Treat strategies Management of HIV discordant couples Cohen IAS 2011
56 Partners PrEP Study 4758 HIV serodiscordant couples (HIV+ partner not yet medically eligible for ART) Randomize HIV partners (normal liver, renal, hematologic function) TDF once daily FTC/TDF once daily Placebo once daily All receiving comprehensive HIV prevention services Follow couples for up to 36 months 1 endpoint: HIV infection in HIV partner Co 1 endpoint: Safety
57 Partners PrEP: Summary TDF and FTC/TDF PrEP definitively reduced risk of HIV acquisition, by 62% & 73%, respectively, in African men and women Similar efficacy between TDF & FTC/TDF HIV protection effect was robust in both women and men Study announcing findings 1.5 years earlier than expected TDF and FTC/TDF PrEP were safe & well tolerated Mild gastrointestinal side effects, predominantly in Month 1 No evidence of risk compensation Baeten IAS 2011
58 So what do these results mean? Guidelines for treatment and prevention likely to change Early treatment of infected adults appears to have major prevention benefits for uninfected partners: should be considered in discordant couples now Pre exposure prophylaxis is effective in reducing risk: adherence is key to successful use. Consideration of targeted use of PrEP in individuals and populations at high risk Implementation strategies need to be developed and funded
59 AIDS: is the end in sight?
60 Aids: is the end in sight? New prevention technologies antiretroviral preexposure prophylaxis, antiretroviral microbicides, male circumcision - provide hope for accelerated reduction in incidence The prevention benefits of antiretroviral treatment are being increasingly recognised Some success in preventive vaccine research Behaviour change remains difficult, but there are some indications of success in young people
61 Roadmap to reversing the epidemic Circumcision Treatment 4 prevention A combined research strategy for biomedical interventions is likely to provide the fastest, most tangible impact on HIV transmission ARV PrEP (oral, microbicide) Shattock et al Science. 2011;333:42-3 Partially effective vaccine Highly effective vaccine HIV incidence Behavioral and structural interventions
62 The Implementation gap We have many ways to prevent HIV infection. The sobering news is that only 20 percent of people who can benefit actually have access to prevention services. We have the scientific capability but there is an imbalance and a gap on the basis of science and on what we can deliver on the basis of public health. Tony Fauci, May 2010
63 Safety is paramount
64 Don t underestimate the stigma of taking ARV Adherence to PMTCT interventions, even as short-term and simple dosing regimens, has been affected by the stigma of treatment, and the fear of side effects Community education and preparation is crucial to success
65 Good regimens are not enough: health systems matter Somewhere over the counter? Good regimens need to reach the people Relying on broken health systems won t work Need for innovative alternatives now: Community distribution New technology (cell phones, internet)
66 Health Systems are in Crisis Wafaa El Sadr, 2009
67 Political will remains essential
68 The crisis of continued funding in the face of a global recession
69 Linking provision of new prevention technologies Prevention of new infections in women Prevention of transmission to sexual partners Prevention of transmission to infants New HIV prevention technologies Family planning & reproductive health services PMTCT services Pre-ART care Antiretroviral therapy Male health care Circumcision
70 The Coalition for Implementation Users Regulatory authorities Researchers Normative Agencies Successful implementation Manufacturers Policymakers Health care providers Media
71 Making the impossible, possible The difficult is what takes a little time; the impossible is what takes a little longer Fridtjof Nansen, ( ) Norwegian explorer, scientist, diplomat, humanitarian and 1922 Nobel Peace Prize Winner
72
Combination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationThe elimination equation: understanding the path to an AIDS-free generation
The elimination equation: understanding the path to an AIDS-free generation James McIntyre Anova Health Institute & School of Public Health & Family Medicine, University of Cape Town Elimination of perinatal
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationCan we treat our way out of the HIV epidemic?
Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationThresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016
Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 1 Objectives of today s lecture Describe global goals in the fight against HIV Review the epidemiology
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationPEP and PrEP: AWAAC 2014
Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationFAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030
Evidence informed, responsive and sustainable care FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030 Alti Zwandor UNAIDS Country Director Maseru, Lesotho 9 December
More informationUnderstanding the Impact of an HIV Intervention Package for Adolescents
Understanding the Impact of an HIV Intervention Package for Adolescents Faikah Bruce Supervisors: Dr. Leigh Johnson (UCT - CIDER) and Prof. Alex Welte (SU - SACEMA) 1 Contents Introduction Literature Review
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationHIV: A global perspective on epidemiology, diagnosis and prevention
HIV: A global perspective on epidemiology, diagnosis and prevention Margaret McLees, M.D., DTMH Instructor, Division of Infectious Diseases Denver Health University of Colorado November 13, 2012 Outline
More informationJames McIntyre & Glenda Gray
James McIntyre & Glenda Gray Thirty years of AIDS July 3, 1981 A generation in the shadow of AIDS... AIDS in South Africa First South African publication: 1983: two cases in homosexual men, both died in
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationReview of planned trials and key emerging issues for Thailand
Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationSuccessful results of clinical trials
Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationCAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina
CAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina Overview Epidemiology of HIV in young people Rationale behind cash transfers Review completed
More informationSix things you need to know
UNAIDS Report 2010 MDG 6 Six things you need to know about the AIDS response today UNAIDS Report 2010 MDG 6 Six things you need to know about the AIDS response today MDG6: Combat HIV/AIDS, Malaria and
More informationUK Department for International Development: Joining forces in the development of new prevention technologies
Speech [Note: Check against delivery] UK Department for International Development: Joining forces in the development of new prevention technologies Challenges in combating the HIV epidemic, combination
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationHHS Public Access Author manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 01.
PrEP adherence patterns strongly impact individual HIV risk and observed efficacy in randomized clinical trials Dobromir T. DIMITROV, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research
More informationM2010 Pre-Conference Workshop, Pittsburgh 22 May 2010
HIV Prevention Research: The Global Picture Presented at: M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010 Salim S. Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director:
More informationPrEP May Cause a Revolution in HIV Prevention: Time to Get Ready
PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready Thomas J. Coates PhD Michael and Sue Steinberg Professor of Global AIDS Research David Geffen School of Medicine University of California,
More informationDr Valérie Martinez-Pourcher
Educa&ng Nurses About An&retrovirals and HIV Preven&on - State of the Science, Uptake Challenges, and Barriers Dr Valérie Martinez-Pourcher Pitié-Salpêtrière Hospital Paris We need to control HIV replication
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationPREPARING FOR PREP: FROM KEY POPULATIONS THEORY TO PRACTICE. Dr Oscar Radebe
PREPARING FOR PREP: FROM THEORY TO PRACTICE KEY POPULATIONS Dr Oscar Radebe PrePARINGFOR THE END OF HIV Until recently there has been exciting new advances in clinical research focusing on HIV prevention
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationHIV / AIDS. Prevention In Our Lives
HIV / AIDS Prevention In Our Lives Prevention In Our Lives: Produced by the Treatment Action Campaign. Authors: Published: September 2010 Conte n t s Introduction: Statistics on HIV in South Africa 2 Why
More informationThe Financial Implications of Reaching Global Treatment and Prevention Goals CHAI slide warehouse
The Financial Implications of Reaching Global Treatment and Prevention Goals CHAI slide warehouse Clinton Health Access Initiative (CHAI) October 2, 2015 As we near global consensus toward test and offer
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationSouth Africa s National HIV Programme. Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH. 23 October 2018
South Africa s National HIV Programme Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH 23 October 2018 Overview The HIV and AIDS sub-programme at NDOH is responsible for: policy formulation, coordination,
More informationThe Beginning of the End of AIDS Diane V. Havlir, MD
The Beginning of the End of AIDS Diane V. Havlir, MD Professor of Medicine University of California, San Francisco AIDS: The Beginning Friedman-Kien, Color Atlas of AIDS AIDS: The Middle Number of people
More informationLinkages between Sexual and Reproductive Health and HIV
Linkages between Sexual and Reproductive Health and HIV Manjula Lusti-Narasimhan Department of Reproductive Health and Research World Health Organization The HIV pandemic 25 years 1981 2006 Rationale for
More informationSexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012
Sexual and Reproductive Health and HIV Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Global estimates of HIV-(2009) People living with HIV 33.3 million [31.4 35.3
More informationHIV and AIDS Estimates
and AIDS Estimates Adults and children living with Adults aged 15 and over living with Women aged 15 and over living with Men aged 15 and over living with 1 300 000 [1 200 000-1 500 000] 1 200 000 [1 100
More informationHIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES JULY 2014 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for
More informationColloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention
Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationTranslating the Science to End New HIV Infections in Kenya
Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of
More informationChildren and AIDS Fourth Stocktaking Report 2009
Children and AIDS Fourth Stocktaking Report 2009 The The Fourth Fourth Stocktaking Stocktaking Report, Report, produced produced by by UNICEF, UNICEF, in in partnership partnership with with UNAIDS, UNAIDS,
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More information90% 90% 90% 30% 10% 5% 70% 90% 95% WHY HIV SELF-TESTING? PLHIV diagnosed PLHIV undiagnosed
WHY HIV SELF-TESTING? In 2014, the United Nations set bold new targets, calling on the global community to ensure that by 2020, 90% of all people living with HIV will know their HIV status, 90% of all
More informationA Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationTransmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa
Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa FIDSSA, Cape Town, November 2017 Quarraisha Abdool Karim, PhD Associate Scientific Director: CAPRISA Professor
More informationHIV : Test and Treat?
HIV : Test and Treat? 14 th HIV Resistance Meeting 22.9.10 Why now? Test and Treat What does it mean? Could it work-what is the evidence? What are the challenges? 1 Universal ART Access 2008 UNAIDS 33
More informationAdolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017
Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa Jessica Haberer, MD, MS November 9, 2017 Disclosures I have no conflicts to declare Grant funding: NIH, Gates
More informationProgress in scaling up HIV prevention and treatment in sub-saharan Africa: 15 years, the state of AIDS
10 th International Workshop on HIV treatment, Pathogenesis and Prevention Research in Resource-Limited setting (INTEREST, 3-6 May, 2016) Progress in scaling up HIV prevention and treatment in sub-saharan
More informationHIV PREP THE NEWEST TOOL IN THE BOX
HIV PREP THE NEWEST TOOL IN THE BOX Infectious Disease Update November 7, 2014 Andrew Petroll, MD, MS Department of Medicine, Division of Infectious Diseases Department of Psychiatry and Behavioral Medicine,
More informationHIV in Zambia MINISTRY OF HEALTH. Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator,
HIV in Zambia Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator, MINISTRY OF HEALTH 8th INTEREST WORKSHOP Intercontinental Hotel, Lusaka May 5 th -9 th, 2013 Background Clinical
More informationWhich Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018
Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018 Outline Scaling up for Impact Critical Point of the Response Choices of strategies Accelerating Implementation
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationHIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE
HIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE THE REMAINING CHALLENGES DR YOGAN PILLAY, NDOH SA HIV CLINICIANS SOCIETY CONFERENCE, CAPE TOWN 25 NOVEMBER, 2012 GLOBAL DATA 34m people living with
More informationDoing studies of ARV based
Doing studies of ARV based microbicides what s s different, what s s the same? Gonasagrie Nair, MBChB, DTM&H, MPH CAPRISA ethekwini Site Project Director & IoR VOICE Trial OVERVIEW Brief historical overview
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationBiomedical HIV Prevention & TaP Treatment as Prevention 2013
Biomedical HIV Prevention & TaP Treatment as Prevention 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationMTN 034/IPM 045: REACH Rings and PrEP in Young Women
MTN 034/IPM 045: REACH Rings and PrEP in Young Women Lulu Nair CRS Leader: Emavundleni -Cape Town On behalf of MTN 034 protocol team MTN Annual Meeting: 2017 Bethesda North Marriott Hotel and Conference
More informationACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS
ACCELERATING HIV COMBINATION PREVENTION HIV COMBINATION PREVENTION INTERVENTIONS Dr T Chidarikire HIV PREVENTION STRATEGIES 13 JUNE 2017 1 Purpose To share the Health Sector HIV Prevention Strategy with
More information